Haley Gittleman YOU? Author Swipe

Last 10y

The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials Open

Elaine Chang, Haley Gittleman, Chi Song, Erik Bloomquist, Laura S. Fernandes , et al. · 2025

Background Retrospective analyses of studies of IO–containing combinations for advanced renal cell carcinoma (RCC) suggest that depth of response is associated with overall survival but have methodological limitations. We investigated the …

Supplementary Table S2 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Treatment-Free Survival and Time on Protocol Therapy With and Without Toxicity in IO-VEGF TKI and Sunitinib Groups

Supplementary Table S2 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Treatment-Free Survival and Time on Protocol Therapy With and Without Toxicity in IO-VEGF TKI and Sunitinib Groups

Supplementary Figure S3 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Time on Each Drug as Monotherapy in IO-TKI Combination

Supplementary Figure S2 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Treatment-Free Survival and Time on Protocol Therapy With and Without Toxicity in IO-VEGF TKI and Sunitinib Groups

Supplementary Table S4 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Timing of Discontinuation of TKI Relative to IO Agent

Supplementary Table S1 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

List of Trials Included in Analysis and Key Design Features

Data from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Purpose:A clinically meaningful attribute of some immune-oncology (IO) regimens is potential durable clinical benefit during a treatment-free interval. We characterize treatment-free survival (TFS) with and without ongoing toxicity in tria…

Supplementary Table S3 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Time on Each Drug as Monotherapy in IO-TKI Combination

Supplementary Table S4 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Timing of Discontinuation of TKI Relative to IO Agent

Supplementary Figure S1 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Treatment-Free Survival in Advanced Renal Cell Carcinoma Trials Evaluating Immuno-Oncology-VEGF TKI Combinations: Sunitinib Group

Supplementary Figure S2 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Treatment-Free Survival and Time on Protocol Therapy With and Without Toxicity in IO-VEGF TKI and Sunitinib Groups

Supplementary Figure S1 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Treatment-Free Survival in Advanced Renal Cell Carcinoma Trials Evaluating Immuno-Oncology-VEGF TKI Combinations: Sunitinib Group

Data from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Purpose:A clinically meaningful attribute of some immune-oncology (IO) regimens is potential durable clinical benefit during a treatment-free interval. We characterize treatment-free survival (TFS) with and without ongoing toxicity in tria…

Supplementary Figure S3 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Time on Each Drug as Monotherapy in IO-TKI Combination

Supplementary Table S3 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

Time on Each Drug as Monotherapy in IO-TKI Combination

Supplementary Table S1 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma Open

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L. Fernandes , et al. · 2024

List of Trials Included in Analysis and Key Design Features

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis Open

Jaleh Fallah, Haley Gittleman, Chana Weinstock, Elaine Chang, Sundeep Agrawal , et al. · 2024

Background This pooled analysis of patient-level data from trials evaluated the clinical outcomes of patients with metastatic renal cell carcinoma with or without cytoreductive nephrectomy before a combination of immune checkpoint inhibito…

A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma Open

Daniel Lee, Haley Gittleman, Chana Weinstock, Daniel L. Suzman, Erik Bloomquist , et al. · 2023

Patients with intermediate/poor-risk metastatic renal cell carcinoma derive an overall survival benefit from immuno-oncology/tyrosine kinase inhibitor combinations, while data for favorable-risk remain immature.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer Open

Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero , et al. · 2023

On November 14, 2022, the FDA granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of adult patients with folate receptor-α (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritonea…

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer Open

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam , et al. · 2022

On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant …

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors Open

Jaleh Fallah, Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford , et al. · 2022

On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RC…

Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores – A pooled analysis of RTOG 0129 and 0522 Open

Musaddiq Awan, Haley Gittleman, Jill S. Barnholtz‐Sloan, Mitchell Machtay, Phuc Félix Nguyen‐Tan , et al. · 2021

Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database Open

Tiffany R. Hodges, Collin M. Labak, Uma V. Mahajan, Christina Huang Wright, James Wright , et al. · 2021

Background The objective of this study was to explore racial/ethnic factors that may be associated with survival in patients with glioblastoma by querying the National Cancer Database (NCDB). Methods The NCDB was queried for patients diagn…

Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016 Open

Rebecca L. Achey, Sierra Vo, Gino Cioffi, Haley Gittleman, Julia Schröer , et al. · 2020

Background Ependymoma is a rare CNS tumor arising from the ependymal lining of the ventricular system. General differences in incidence and survival have been noted but not examined on a comprehensive scale for all ages and by histology. D…

Autologous Fat Transfer for Scar Prevention and Remodeling: A Randomized, Blinded, Placebo-controlled Trial Open

JC Brown, Hulan Shang, Ning Yang, Justine Pierson, Catherine R. Ratliff , et al. · 2020

Background: Autologous fat transfer—also referred to as fat grafting—has been reported to provide beneficial effects to overlying scar and skin. Despite procedural frequency, there is a paucity of high-level evidence guiding the surgeon in…

Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014 Open

Quinn T. Ostrom, Gabrielle Truitt, Haley Gittleman, Daniel J. Brat, Carol Kruchko , et al. · 2019

Background The majority of reported cancer survival statistics in the United States are generated using the National Cancer Institute’s publicly available Surveillance, Epidemiology, and End Results (SEER) data, which prior to 2019 represe…

Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995–2015 Open

Faith G. Davis, Trenton Smith, Haley Gittleman, Quinn T. Ostrom, Carol Kruchko , et al. · 2019

An independently validated survival nomogram for lower-grade glioma Open

Haley Gittleman, Andrew E. Sloan, Jill S. Barnholtz‐Sloan · 2019

Background Gliomas are the most common primary malignant brain tumor. Diffuse low-grade and intermediate-grade gliomas, which together compose the lower-grade gliomas (LGGs; World Health Organization [WHO] grades II and III), present a the…

A Nomogram for Outcomes after Chemoradiation for Non-HPV-Related Squamous Cell Carcinomas of the Head and Neck – A Pooled Analysis of NRG Oncology RTOG 0129 and 0522 Open

Musaddiq Awan, Haley Gittleman, Jill S. Barnholtz‐Sloan, Mitchell Machtay, Phuc Félix Nguyen‐Tan , et al. · 2019

Fetching topic information...